[New developments in neonatal screening]. / Nouveautés dans le dépistage néonatal.

NEW DEVELOPMENTS IN NEONATAL SCREENING. The French national newborn screening program (NBS) celebrated its 50th anniversary in 2022. A few drops of blood are drawn between 48 and 72 hours of life for each newborn on a filter paper and entrusted to a Regional Center for Newborn Screening, which analyses it diligently. When the result is beyond a threshold, the baby and its parents are summoned to a specialized paediatric department. If the suspected disease is confirmed, specific care can be started in time to avoid or limit a disability. Each year, nearly 1.000 sick children are diagnosed by NBS in France, and treated in a specialized hospital team. The 2018 National Rare Disease Plan has relaunched the NBS process. Until then, 7 diseases whose hearing loss were detected. Since then, 7 other diseases have been added to the program, and others were recommended or are being assessed, opening a new page in the history of NBS in France.

NOUVEAUTÉS DANS LE DÉPISTAGE NÉONATAL. Le programme national de dépistage néonatal a fêté ses 50 ans en 2022. Quelques gouttes de sang sont prélevées entre 48 et 72 heures de vie de chaque nouveau-né sur un buvard. Celui-ci est confié à un centre régional de dépistage néonatal (CRDN) qui en assure l'analyse rapidement afin que le résultat, s'il est au-delà d'un seuil, permette à l'enfant et sa famille d'être reçus dans un service pédiatrique spécialisé. Si la maladie suspectée est confirmée, la prise en charge spécifique peut débuter à temps pour éviter ou limiter un handicap. Chaque année, près de 1 000 enfants malades sont diagnostiqués grâce à ce dépistage en France, et pris en charge par une équipe hospitalière spécialisée. Le Plan national maladies rares de 2018 a relancé la dynamique du dépistage : jusqu'alors, sept maladies (dont la surdité) étaient dépistées ; depuis, sept autres maladies ont été ajoutées au programme, et d'autres ont été recommandées ou sont en cours d'évaluation, ouvrant une nouvelle page dans l'histoire du dépistage néonatal en France.

The Ultrasound-Assisted Extraction of Polyphenols from Mexican Firecracker (Hamelia patens Jacq.): Evaluation of Bioactivities and Identification of Phytochemicals by HPLC-ESI-MS.

The objective of the present work was to optimize the extraction of phytochemicals from Hamelia patens Jacq. by ultrasound-assisted extraction. Taguchi L9 orthogonal array was used to evaluate the factors solid/liquid ratio (1:8, 1:12, and 1:16), extraction time (10, 20, and 30 min), and ethanol concentration (0, 35, and 70%). Total polyphenols were the response variable. Chromatographic fractionation using Amberlite XAD-16 was carried out and the total polyphenols, flavonoids, and condensed tannins were quantified. The redox potential, the reduction of the 2,2-diphenyl-1-picrylhydrazyl (DPPH), and the lipid oxidation inhibition were determined. Anti-bacterial activity was evaluated. The phytochemicals were identified by liquid chromatography coupled to mass spectrometry. Optimal extraction conditions were a solid/liquid ratio of 1:16, ethanol of 35%, and 10 min of ultrasound-assisted extraction. Maximum polyphenol content in the crude extract was 1689.976 ± 86.430 mg of gallic acid equivalents (GAE)/100 g of dried plant material. The purified fraction showed a total polyphenols content of 3552.84 ± 7.25 mg of GAE, flavonoids 1316.17 ± 0.27 mg of catechin equivalents, and condensed tannins 1694.87 ± 22.21 mg of procyanidin B1 equivalents, all per 100 g of purified fraction. Its redox potential was 553.93 ± 1.22 mV, reducing 63.08 ± 0.42% of DPPH radical and inhibiting 77.78 ± 2.78% of lipid oxidation. The polyphenols demonstrated antibacterial activity against Escherichia coli, Klebsiella pneumonia, and Enterococcus faecalis. The HPLC-ESI-MS analysis revealed the presence of coumarins, hydroxycinnamic acids, and flavonoids.

Automated detection of patient movement during a CBCT scan based on the projection data.

OBJECTIVES: To develop an automated procedure to detect patient motion on the projection images acquired during a cone beam computed tomography (CBCT) scan and to evaluate the method's feasibility on small real-world CBCT images in relation to visual assessment. METHODS: Based on optical flow theory, software was developed using the sequence of the projection images of a CBCT machine for automated detection of patient motion. Averaged acceleration vectors were used as measurement data and compared with visual assessment of the projection images displayed as video. Seventy-nine CBCT data sets (small field-of-view: 40 mm) from our patient database were selected in a sequential fashion and evaluated with the software. RESULTS: 10 out of 79 (13%) were allocated to a patient movement. A threshold of 0.4 pixel/frame transition was empirically determined as indicating motion by visual assessment of the image sequence. Relative to this standard of reference, the software reached 80% sensitivity versus 67% specificity. CONCLUSIONS: Optical flow seems to be an efficient concept for automated detection of patient motion on the projection images acquired during a CBCT scan.

Ophthalmic features of PLA2G6-related paediatric neurodegeneration with brain iron accumulation.

BACKGROUND: Neurodegeneration with brain iron accumulation (NBIA) refers to genetically heterogenous paediatric neurodegenerative disorders characterised by basal ganglia iron deposition. One major cause is recessive mutations in the PLA2G6 gene. While strabismus and optic nerve pallor have been reported for PLA2G6-related disease, the ophthalmic phenotype is not carefully defined. In this study we characterise the ophthalmic phenotype of PLA2G6-related NBIA. METHODS: Prospective cohort study. RESULTS: The eight patients were 4-26 years old when examined. All had progressive cognitive and motor regression first noted between 9 months and 6 years of age that typically first manifested as difficulty walking (ataxia). Ophthalmic examination was sometimes limited by cognitive ability. Four of eight had exotropia, 7/7 bilateral supraduction defect, 5/7 poor convergence, 6/8 saccadic pursuit, 4/8 saccadic intrusions that resembled square-wave jerks, and 8/8 bilateral optic nerve head pallor. All patients lacked Bell phenomenon. CONCLUSIONS: Upgaze palsy, although not a previously reported finding, was confirmed in all patients (except in one for whom assessment could not be performed) and thus can be considered part of the phenotype in children and young adults. Other frequent findings not previously highlighted were abnormal convergence, saccadic pursuit, and saccadic intrusions. Optic nerve head pallor and strabismus, previously reported findings in the disease, were found in 100% and 50% of our cohort, respectively, and the strabismus in our series was always exotropia. Taken together, these clinical findings may be helpful in distinguishing PLA2G6-related neurodegeneration from the other major cause of NBIA, recessive PANK2 mutations.